96 related articles for article (PubMed ID: 20231781)
1. Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132.
Ujino S; Yamaguchi S; Shimotohno K; Takaku H
Antivir Chem Chemother; 2010 Mar; 20(4):161-7. PubMed ID: 20231781
[TBL] [Abstract][Full Text] [Related]
2. Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3.
Ujino S; Yamaguchi S; Shimotohno K; Takaku H
J Biol Chem; 2009 Mar; 284(11):6841-6. PubMed ID: 19150985
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice.
Nakagawa S; Umehara T; Matsuda C; Kuge S; Sudoh M; Kohara M
Biochem Biophys Res Commun; 2007 Feb; 353(4):882-8. PubMed ID: 17196931
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90.
Okamoto T; Nishimura Y; Ichimura T; Suzuki K; Miyamura T; Suzuki T; Moriishi K; Matsuura Y
EMBO J; 2006 Oct; 25(20):5015-25. PubMed ID: 17024179
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
7. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Pelicano H; Carew JS; McQueen TJ; Andreeff M; Plunkett W; Keating MJ; Huang P
Leukemia; 2006 Apr; 20(4):610-9. PubMed ID: 16482209
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy.
Tsou YL; Lin YW; Chang HW; Lin HY; Shao HY; Yu SL; Liu CC; Chitra E; Sia C; Chow YH
PLoS One; 2013; 8(10):e77133. PubMed ID: 24098578
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
10. The 26S proteasome function and Hsp90 activity involved in the regulation of HsfA2 expression in response to oxidative stress.
Nishizawa-Yokoi A; Tainaka H; Yoshida E; Tamoi M; Yabuta Y; Shigeoka S
Plant Cell Physiol; 2010 Mar; 51(3):486-96. PubMed ID: 20147301
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific.
Xu L; Zhou X; Peppelenbosch MP; Pan Q
Arch Virol; 2015 Feb; 160(2):435-9. PubMed ID: 25476751
[TBL] [Abstract][Full Text] [Related]
12. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
13. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
Yao Q; Weigel B; Kersey J
Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine.
Varela-M RE; Mollinedo-Gajate C; Muro A; Mollinedo F
Acta Trop; 2014 Mar; 131():32-6. PubMed ID: 24299925
[TBL] [Abstract][Full Text] [Related]
15. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
Sato A; Asano T; Ito K; Asano T
Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
J Mol Med (Berl); 2006 Aug; 84(8):635-46. PubMed ID: 16741751
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy.
Mizui T; Yamashina S; Tanida I; Takei Y; Ueno T; Sakamoto N; Ikejima K; Kitamura T; Enomoto N; Sakai T; Kominami E; Watanabe S
J Gastroenterol; 2010 Feb; 45(2):195-203. PubMed ID: 19760134
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
19. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
